Altimmune (ALT) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.20, -6.78% vs the prior close of $2.36.
- Volume 4.23M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ALT slides 6.8% to $2.20, a 52-week low. Closed at $2.20, -6.78% vs the prior close of $2.36. Day range $2.17–$2.37, opened at $2.36.
ALT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ALT slides 6.8% to $2.20, a 52-week low
- Closed at $2.20, -6.78% vs the prior close of $2.36. Day range $2.17–$2.37, opened at $2.36.
- Volume was 4.23M shares, 1.0x its 50-day average of 4.09M.
- Price is -26.6% vs its 50-day average ($3.00) and -34.8% vs its 200-day average ($3.37).
- 52-week range $2.17–$6.44; today's close sits at 1% of that range, 65.8% below the 52-week high.
Oct 15, 2026 — ALT rises 2.2% to $2.36
- Closed at $2.36, +2.16% vs the prior close of $2.31. Day range $2.29–$2.38, opened at $2.31.
- Volume was 3.34M shares, 0.8x its 50-day average of 4.08M.
- Price is -21.7% vs its 50-day average ($3.01) and -30.2% vs its 200-day average ($3.38).
- 52-week range $2.29–$6.44; today's close sits at 2% of that range, 63.4% below the 52-week high.
Oct 14, 2026 — ALT slides 4.9% to $2.31, a 52-week low, 3 down days in a row
- Closed at $2.31, -4.94% vs the prior close of $2.43. Day range $2.29–$2.41, opened at $2.40.
- Volume was 5.62M shares, 1.4x its 50-day average of 4.13M.
- Price is -23.7% vs its 50-day average ($3.03) and -31.8% vs its 200-day average ($3.39).
- 52-week range $2.29–$6.44; today's close sits at 0% of that range, 64.1% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ALT slides 5.1% to $2.43, a 52-week low
- Closed at $2.43, -5.08% vs the prior close of $2.56. Day range $2.43–$2.56, opened at $2.56.
- Volume was 3.71M shares, 0.9x its 50-day average of 4.15M.
- Price is -20.1% vs its 50-day average ($3.04) and -28.4% vs its 200-day average ($3.40).
- 52-week range $2.43–$6.44; today's close sits at 0% of that range, 62.3% below the 52-week high.
Oct 12, 2026 — ALT dips 1.9% to $2.56, a 52-week low
- Closed at $2.56, -1.92% vs the prior close of $2.61. Day range $2.56–$2.62, opened at $2.59.
- Volume was 2.16M shares, 0.5x its 50-day average of 4.19M — lighter than usual.
- Price is -16.1% vs its 50-day average ($3.05) and -24.8% vs its 200-day average ($3.40).
- 52-week range $2.55–$6.44; today's close sits at 0% of that range, 60.2% below the 52-week high.
Oct 9, 2026 — ALT rises 0.4% to $2.61
- Closed at $2.61, +0.38% vs the prior close of $2.60. Day range $2.57–$2.64, opened at $2.60.
- Volume was 2.68M shares, 0.6x its 50-day average of 4.24M.
- Price is -14.7% vs its 50-day average ($3.06) and -23.5% vs its 200-day average ($3.41).
- 52-week range $2.55–$6.44; today's close sits at 2% of that range, 59.5% below the 52-week high.
Oct 8, 2026 — ALT dips 2.3% to $2.60, a 3-month low, 7 down days in a row
- Closed at $2.60, -2.26% vs the prior close of $2.66. Day range $2.55–$2.66, opened at $2.66.
- Volume was 4.93M shares, 1.1x its 50-day average of 4.31M.
- Price is -15.2% vs its 50-day average ($3.07) and -23.9% vs its 200-day average ($3.42).
- 52-week range $2.55–$6.44; today's close sits at 1% of that range, 59.6% below the 52-week high.
- That makes 7 straight losses.
Oct 7, 2026 — ALT dips 0.4% to $2.66, a 3-month low, 6 down days in a row
- Closed at $2.66, -0.37% vs the prior close of $2.67. Day range $2.63–$2.74, opened at $2.64.
- Volume was 3.17M shares, 0.7x its 50-day average of 4.59M.
- Price is -13.4% vs its 50-day average ($3.07) and -22.3% vs its 200-day average ($3.42).
- 52-week range $2.56–$6.44; today's close sits at 3% of that range, 58.7% below the 52-week high.
- That makes 6 straight losses.
Oct 6, 2026 — ALT ends flat (+0.0%) to $2.67, 5 down days in a row
- Closed at $2.67, +0.00% vs the prior close of $2.67. Day range $2.64–$2.70, opened at $2.70.
- Volume was 7.62M shares, 1.7x its 50-day average of 4.52M.
- Price is -13.3% vs its 50-day average ($3.08) and -22.3% vs its 200-day average ($3.44).
- 52-week range $2.56–$6.44; today's close sits at 3% of that range, 58.5% below the 52-week high.
- That makes 5 straight losses.
Oct 5, 2026 — ALT dips 2.4% to $2.67, a 3-month low, 4 down days in a row
- Closed at $2.67, -2.38% vs the prior close of $2.73. Day range $2.65–$2.75, opened at $2.73.
- Volume was 3.84M shares, 0.9x its 50-day average of 4.48M.
- Price is -13.4% vs its 50-day average ($3.08) and -22.6% vs its 200-day average ($3.45).
- 52-week range $2.56–$6.44; today's close sits at 3% of that range, 58.5% below the 52-week high.
- That makes 4 straight losses.
Oct 2, 2026 — ALT dips 0.9% to $2.73, a 3-month low, 3 down days in a row
- Closed at $2.73, -0.91% vs the prior close of $2.76. Day range $2.71–$2.81, opened at $2.80.
- Volume was 4.24M shares, 1.0x its 50-day average of 4.43M.
- Price is -11.4% vs its 50-day average ($3.09) and -21.0% vs its 200-day average ($3.46).
- 52-week range $2.56–$6.44; today's close sits at 5% of that range, 57.5% below the 52-week high.
- That makes 3 straight losses.
ALT latest news & SEC filings
Every SEC filing by or about ALT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Arbet-Engels Christophe converted options/RSUs into 37,500 shares on Oct 1, 2026; now holds 37,500
- Arbet-Engels Christophe had withheld for taxes 12,679 shares at $2.76 (≈$34.99K) on Oct 1, 2026; now holds 24,821
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Weaver Gregory L converted options/RSUs into 14,475 shares on Oct 1, 2026; now holds 54,306
- Weaver Gregory L had withheld for taxes 4,379 shares at $2.76 (≈$12.09K) on Oct 1, 2026; now holds 49,927
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Richardson Linda M converted options/RSUs into 24,000 shares on Sep 16, 2026; now holds 24,000
- Richardson Linda M had withheld for taxes 6,826 shares at $3.24 (≈$22.12K) on Sep 16, 2026; now holds 17,174
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Durso Jerome Benedict bought 15,000 shares at $2.95 (≈$44.25K) on Aug 13, 2026
- Durso Jerome Benedict bought 15,000 shares at $2.95 (≈$44.25K) on Aug 13, 2026
- Durso Jerome Benedict bought 15,000 shares at $2.95 (≈$44.25K) on Aug 13, 2026
- Durso Jerome Benedict bought 15,000 shares at $2.95 (≈$44.25K) on Aug 13, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2025:
- Revenue: $5.00K
- Net income: -$22.82M (prior year -$22.15M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.12 (prior year -$0.27) (loss narrowed vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade ALT
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 5, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.73% (largest 6.8%).
- Liquidity: about 3.93M shares (≈$8.64M) trade per day on average.
- 52-week position: $2.20 vs a range of $2.17–$6.44 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Jerome Benedict Durso bought 15,000 shares on Aug 13, 2026.
- Latest filings: 8-K Sep 29, 2026; 10-Q Aug 12, 2026; 8-K Aug 12, 2026.
- Share count: 194.52M shares outstanding (Aug 7, 2026), +120.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ALT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.36 | 2.37 | 2.17 | 2.20 | 4.23M |
| Oct 15, 2026 | 2.31 | 2.38 | 2.29 | 2.36 | 3.34M |
| Oct 14, 2026 | 2.40 | 2.41 | 2.29 | 2.31 | 5.62M |
| Oct 13, 2026 | 2.56 | 2.56 | 2.43 | 2.43 | 3.71M |
| Oct 12, 2026 | 2.59 | 2.62 | 2.56 | 2.56 | 2.16M |
| Oct 9, 2026 | 2.60 | 2.64 | 2.57 | 2.61 | 2.68M |
| Oct 8, 2026 | 2.66 | 2.66 | 2.55 | 2.60 | 4.93M |
| Oct 7, 2026 | 2.64 | 2.74 | 2.63 | 2.66 | 3.17M |
| Oct 6, 2026 | 2.70 | 2.70 | 2.64 | 2.67 | 7.62M |
| Oct 5, 2026 | 2.73 | 2.75 | 2.65 | 2.67 | 3.84M |
| Oct 2, 2026 | 2.80 | 2.81 | 2.71 | 2.73 | 4.24M |
| Oct 1, 2026 | 2.85 | 2.85 | 2.75 | 2.76 | 3.59M |
| Sep 30, 2026 | 2.99 | 2.99 | 2.86 | 2.86 | 4.92M |
| Sep 29, 2026 | 2.99 | 3.01 | 2.92 | 2.97 | 2.56M |
| Sep 28, 2026 | 3.04 | 3.07 | 2.95 | 2.96 | 3.36M |
| Sep 25, 2026 | 3.05 | 3.11 | 3.00 | 3.06 | 2.86M |
| Sep 24, 2026 | 3.18 | 3.20 | 2.98 | 3.04 | 3.69M |
| Sep 23, 2026 | 3.42 | 3.42 | 3.15 | 3.19 | 4.53M |
| Sep 22, 2026 | 3.33 | 3.41 | 3.25 | 3.41 | 4.00M |
| Sep 21, 2026 | 3.31 | 3.34 | 3.24 | 3.27 | 3.52M |
About Altimmune
Altimmune (ALT) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in GAITHERSBURG, MD. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1326190.
ALT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jerome Benedict Durso | President and CEO | Aug 13, 2026 |
| John Gill | Director | May 1, 2026 |
| Vipin K Garg | Director | Feb 2, 2026 |
| Philip Hodges | Director | May 1, 2026 |
| Diane Jorkasky | Director | May 1, 2026 |
| Teri L Lawver | Director | May 1, 2026 |
| Wayne Pisano | Director | May 1, 2026 |
| Mitchel Sayare | Director | May 1, 2026 |
| Klaus Schafer | Director | May 1, 2026 |
| Catherine A. Sohn | Director | May 1, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christophe Arbet-Engels | Chief Medical Officer | Oct 3, 2025 |
| Jerome Benedict Durso | President and CEO | Aug 13, 2026 |
| Raymond M Jordt | Chief Business Officer | Feb 2, 2026 |
| Linda M Richardson | Chief Commercial Officer | Sep 17, 2026 |
| M Scot Roberts | Chief Scientific Officer | Aug 3, 2026 |
| Gregory L Weaver | Chief Financial Officer | Aug 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 13, 2026 | Jerome Benedict Durso | Buy | 15,000 | $2.95 |
| Aug 13, 2026 | Jerome Benedict Durso | Buy | 15,000 | $2.95 |
| Aug 13, 2026 | Jerome Benedict Durso | Buy | 15,000 | $2.95 |
| Aug 13, 2026 | Jerome Benedict Durso | Buy | 15,000 | $2.95 |
| Apr 6, 2026 | John Gill | Buy | 9,200 | $3.41 |
| Apr 6, 2026 | John Gill | Buy | 9,200 | $3.41 |
| Apr 6, 2026 | John Gill | Buy | 9,200 | $3.41 |
| Apr 6, 2026 | John Gill | Buy | 9,200 | $3.41 |
| Apr 1, 2026 | Jerome Benedict Durso | Buy | 15,000 | $3.14 |
| Apr 1, 2026 | Jerome Benedict Durso | Buy | 15,000 | $3.14 |
| Apr 1, 2026 | Jerome Benedict Durso | Buy | 15,000 | $3.14 |
| Apr 1, 2026 | Jerome Benedict Durso | Buy | 15,000 | $3.14 |
| Apr 1, 2026 | Gregory L Weaver | Buy | 10,000 | $3.15 |
| Apr 1, 2026 | Gregory L Weaver | Buy | 10,000 | $3.15 |
| Apr 1, 2026 | Gregory L Weaver | Buy | 10,000 | $3.15 |
ALT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-88.09M | -1.00 | $-67.53M |
| Dec 31, 2024 | — | $-95.06M | -1.34 | $-79.85M |
| Dec 31, 2023 | — | $-88.45M | -1.66 | $-75.81M |
| Dec 31, 2022 | — | $-84.71M | -1.81 | $-62.59M |
| Dec 31, 2021 | $4.41M | $-97.09M | -2.35 | $-78.24M |
Latest balance sheet: total assets $527.21M, total liabilities $53.00M, cash $63.01M (as of Jun 30, 2026).
ALT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $2.93 |
| May 13, 2026 | 8-K Item 2.02 (results) | $3.02 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $3.51 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $3.94 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $3.62 |
| May 13, 2025 | 8-K Item 2.02 (results) | $5.76 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $6.42 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $9.49 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ALT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.